Table 2 Contrasts of the AFT model lognormal for overall survival.

From: Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

Factor

Contrast

TR CI 95%

NLR

Continuous

0.88 (0.81–0.95)

CEA, ng/ml

240 vs 15.7

0.67 (0.53–0.85)

Time to trifluridine/tipiracil

44.0 vs 18.5

1.11 (0.90–1.36)

Alkaline phosphatase, IU/L

302 vs 113

0.86 (0.69–1.06)

ECOG PS

1 vs 0

1.23 (0.86–1.76)

 

2 vs 1

0.52 (0.38–0.72)

 

3 vs 1

0.24 (0.08–0.73)

KRAS/NRAS/BRAF mutation

Yes vs No

0.84 (0.62–1.08)

  1. AFT, accelerated failure time; NLR, Neutrophil–lymphocyte ratio; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; sd, standard deviation; TR, time ratio; CI, confidence interval.
Back to article page